This article presents the anti-infective treatment and pharmaceutical care of an elderly patient with liver cirrhosis complicated with severe psittacosis. Based on the pathophysiological characteristics of infection in patients with severe liver diseases and in combination with relevant guidelines, the combined regimen of omadacycline + moxifloxacin was adopted to treat psittacosis. In case of recurrent episodes, Aspergillus fumigata was detected in the metagenomic next-generation sequencing of bronchoalveolar lavage fluid. Initially, voriconazole was administered for treatment, and later switched to posaconazole. Additionally, clinical pharmacists provided pharmaceutical care encompassing adverse reaction monitoring and voriconazole therapeutic drug monitoring. The patient's infection was effectively controlled, body temperature returned to normal, white blood cell counts and platelet counts basically returned to normal range, serum high-sensitive C-reactive protein, procalcitonin, and other inflammatory indicators significantly decreased, and the patient was discharged. Clinical pharmacists assisted clinicians in formulating a reasonable anti-psittacosis treatment plan and provided individualized pharmaceutical care to ensure the effectiveness and safety of clinical drug treatment.

1.中国研究型医院学会肝病专业委员会重症肝病学组, 中华医学会肝病学分会重型肝病与人工肝学组. 重症肝病合并侵袭性真菌感染诊治专家共识[J]. 中华肝脏病杂志, 2022, 30(2): 159-168. [Severe Liver Disease Group, the Professional Committee for Hepatology, Chinese Research Hospital Association, Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Consensus on diagnosis and treatment of invasive fungal infection in patients with severe liver disease[J]. Chinese Journal of Hepatology, 2022, 30(2): 159-168.] DOI: 10.3760/cma.j.cn501113-20220130-00053.

2.中国医院协会临床微生物实验室专委会, 中国老年医学学会检验医学分会感染性疾病学组. 鹦鹉热诊疗中国专家共识[J]. 中华临床感染病杂志, 2024, 17(3): 191-204.[Clinical Microbiology Laboratory Committee, Chinese Hospital Association. Chinese expert consensus on diagnosis and treatment of psittacosis[J]. Chinese Journal of Clinical Infectious Diseases, 2024, 17(3): 191-204.] DOI: 10.3760/cma.j.issn.1674-2397. 2024.03.002.

3.Fang C, Xu L, Tan J, et al. Omadacycline for the treatment of severe Chlamydia psittaci pneumonia complicated with multiple organ failure：a case report[J]. Infect Drug Resist, 2022, 15: 5831-5838. DOI: 10.2147/IDR.S384296.

4.Li H, Mao X, Wu Z, et al. Omadacycline in the treatment of Chlamydia psittaci pneumonia: a retrospective study on efficacy and safety[J]. Br J Hosp Med (Lond), 2024, 85(11): 1-12. DOI: 10.12968/hmed.2024.0381.

5.刘辉, 叶静, 杨进, 等. 23例鹦鹉热肺炎临床特征分析[J]. 临床肺科杂志, 2022, 27(3): 346-350. [Liu H, Ye J, Yang J, et al. Analysis of clinical features of 23 patients with psittacosis pneumonia[J]. Journal of Clinical Pulmonary Medicine, 2022, 27(3): 346-350.] DOI: 10.3969/j.issn.1009-6663.2022.03.005.

6.杜晓红, 李淑芬, 张丽. 1例社区获得性鹦鹉热衣原体肺炎的病例分析[J]. 中国抗生素杂志, 2022, 47(3): 309-312. [Du XH, Li SF, Zhang L. A case analysis of community-acquired Chlamydia psittaci pneumonia[J]. Chinese Journal of Antibiotics, 2022, 47(3): 309-312.] DOI: 10.3969/j.issn.1001-8689.2022.03.017.

7.中华医学会呼吸病学分会. 中国成人社区获得性肺炎诊断和治疗指南（2016年版）[J]. 中华结核和呼吸杂志, 2016, 39(4): 253-279. DOI: 10.3760/cma.j.issn.1001-0939.2016.04.005.

8.中华医学会呼吸病学分会. 下呼吸道感染宏基因组二代测序报告临床解读路径专家共识[J]. 中华结核和呼吸杂志, 2023, 46(4): 322-335. [Chinese Thoracic Society. Consensus of clinical pathways of metagenomic next-generation sequencing test in diagnosis of lower respiratory tract infections in China[J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2023, 46(4): 322-335.] DOI: 10.3760/cma.j.cn112147-20220701-00553.

9.中国医疗保健国际交流促进会临床微生物学分会, 中华医学会检验医学分会临床微生物学组, 中华医学会微生物学和免疫学分会微生物学组. 侵袭性真菌病真菌学检查指南[J]. 中华检验医学杂志, 2023, 46(6): 541-557. [Clinical Microbiology Society of the China Association for the Promotion of International Exchange in Healthcare, Clinical Microbiology Group of the Laboratory Medicine Society of the Chinese Medical Association, Clinical Microbiology Group of the Microbiology and Immunology Society of the Chinese Medical Association. Guidelines on mycology examination of invasive fungal diseases[J]. Chinese Journal of Laboratory Medicine, 2023, 46(6): 541-557.] DOI: 10.3760/cma.j.cn114452-20230126-00046.

10.唐晓丹, 李光辉. 2016年美国感染病学会曲霉病诊断处理实践指南[J]. 中国感染与化疗杂志, 2017, 17(4): 456-462. [Tang XD, Li GH. The interpretation of practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America[J]. Chinese Journal of Infection and Chemotherapy, 2017, 17(4): 456-462.] DOI: 10.16718/j.1009-7708.2017.04.021.

11.Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium[J]. Clin Infect Dis, 2020, 71(6): 1367-1376. DOI: 10.1093/cid/ciz1008.

12.Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline[J]. Clin Microbiol Infect, 2018, 24Suppl 1: e1-e38. DOI: 10.1016/j.cmi.2018.01.002.

13.Chen K, Zhang X, Ke X, et a1. 1ndividalized medication of voriconazole: a practice guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society[J]. Ther Drug Monit, 2018, 40(6): 663-674. DOI: 10.1097/FTD. 0000000000000561.

14.泊沙康唑临床应用专家组. 泊沙康唑临床应用专家共识（2022版）[J]. 中华临床感染病杂志, 2022, 15(5): 321-332. [Working Group of Expert Consensus on Clinical Use of Posaconazole. Expert consensus on clinical use of posaconazole(2022 edition)[J]. Chinese Journal of Clinical Infectious Diseases, 2022, 15(5): 321-332.] DOI: 10.3760/cma.j.issn.1674-2397.2022.05.001.

15.邓万俊. 氟喹诺酮类抗生素的心脏毒性[J]. 国外医药（抗生素分册）, 2004, 25(5): 198-201. DOI: 10.3969/j.issn.1001-8751. 2004.05.002.

16.孙忠实, 朱珠. 氟喹诺酮类药物与其所致QT间期延长 [J]. 中国药物警戒, 2004, 1(2): 38-39. [Sun ZS, Zhu Z. Fluoroquinolones and the lengthening of QT interval[J]. Chinese Journal of Pharmacovigilance, 2004, 1(2): 38-39.] DOI: 10.3969/j.issn.1672-8629.2004.02.013.

17.袁智龙, 范亚新, 龚媛媛, 等. 泊沙康唑治疗药物监测研究进展[J]. 中国感染与化疗杂志, 2023, 23(6): 777-786. [Yuan ZL, Fan YX, Gong YY, et a1. Research advances in therapeutic drug monitoring of posaconazole [J]. Chinese Journal of Infection and Chemotherapy, 2023, 23(6): 777-786.] DOI: 10.16718/j.1009-7708.2023.06.019.

18.毛新慧, 王华玉, 王荣环. 泊沙康唑致不良反应文献分析[J]. 中国新药杂志, 2022, 31(19): 1962-1968. [Mao XH, Wang HY, Wang RH. Literature analysis of adverse drug reactions caused by posaconazole[J]. Chinese Journal of New Drugs, 2022, 31(19): 1962-1968.] DOI: 10.3969/j.issn.1003-3734.2022.19.015.